Cargando…
Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer
KRAS mutated circulating tumor DNA (MctDNA) can be monitored in the blood of patients with metastatic colorectal cancer (mCRC), but dynamic changes have not been determined. Four hundred and fifty-seven plasma samples were collected prospectively from 85 mCRC patients who underwent chemotherapy. Mct...
Autores principales: | Takayama, Yuji, Suzuki, Koichi, Muto, Yuta, Ichida, Kosuke, Fukui, Taro, Kakizawa, Nao, Ishikawa, Hideki, Watanabe, Fumiaki, Hasegawa, Fumi, Saito, Masaaki, Tsujinaka, Shingo, Futsuhara, Kazushige, Miyakura, Yasuyuki, Noda, Hiroshi, Konishi, Fumio, Rikiyama, Toshiki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966256/ https://www.ncbi.nlm.nih.gov/pubmed/29849949 http://dx.doi.org/10.18632/oncotarget.25309 |
Ejemplares similares
-
Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis
por: Suzuki, Koichi, et al.
Publicado: (2017) -
Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report
por: Fukui, Taro, et al.
Publicado: (2019) -
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer
por: Watanabe, Fumiaki, et al.
Publicado: (2019) -
Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients
por: Watanabe, Fumiaki, et al.
Publicado: (2021) -
Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
por: Tamaki, Sawako, et al.
Publicado: (2022)